Regeneron Pharmaceuticals (REGN) Free Cash Flow (2009 - 2026)

Regeneron Pharmaceuticals' Free Cash Flow history runs 18 years deep, the most recent figure standing at $848.3 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 3.98% year-over-year to $848.3 million; the TTM figure through Mar 2026 stood at $4.1 billion (up 32.6% YoY), while the FY2025 annual figure was $4.1 billion, up 11.35% from the prior year.
• Free Cash Flow was $848.3 million for Q1 2026 at Regeneron Pharmaceuticals, down from $922.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.0 billion in Q1 2022 to a low of $336.3 million in Q2 2024.
• Historically, Free Cash Flow has averaged $993.7 million across 5 years, with a median of $922.0 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 85.17% in 2022, then jumped 255.31% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $1.6 billion in 2022, then slumped by 46.53% to $838.3 million in 2023, then climbed by 26.83% to $1.1 billion in 2024, then fell by 13.28% to $922.0 million in 2025, then declined by 7.99% to $848.3 million in 2026.
• The last three Free Cash Flow figures came in at $848.3 million (Q1 2026), $922.0 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.